Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer

Inclusion Criteria: * Histologic proof of infiltrating duct carcinoma of breast. * Her-2 negative tumors. * ECOG performance status: 0-1. * Presence of measurable disease: primary and/or metastatic. * CBC showing normal values or any toxicity limited to grade I. * SMA showing liver and renal functions \< 1.5 normal values * previous treatment with an anthracycline and with a taxane is mandatory either as neoadjuvant/adjuvant treatment or for metastatic disease. * previous treatment by chemotherapy for metastatic disease is allowed (up to three lines, allowing for MTD Capecitabine to be one of them). * previous treatment by a bisphosphonate is allowed. However,those patients who up to the study had not received any bisphosphonate and those who had received Clodronate- will receive Pamidronate; those who had been under Pamidronate- will receive Zoledronate; those who had been under Zoledronate- will continue with it." * The patient's signature on the informed consent. Exclusion Criteria: * Her-2 neu positive tumor * Inability to visit the clinic for outpatient treatment and evaluation * Active/symptomatic brain metastases. * ECOG performance status: 2-4. * Presence of Hand -Foot syndrome, at grade \> 2. * CBC with any grade \>2 toxicity * SMA showing liver functions \> 1.5 normal values * SMA showing renal functions \> normal values -Current continuous treatment by steroids or by NSAIDs, or by anti- coagulants for "non protocol" reasons. * presence of exclusively non-measurable disease (I/E: exclusive bone disease with non-representative tumor markers). * previous radiotherapy to the "only measurable disease". * pleural or peritoneal effusion that may represent a "third space". * history of active peptic ulcer. * symptomatic coronary heart disease.